Zhao W.,Comprehensive Therapy Qingdao Central Hospital |
Wei H.,Comprehensive Therapy Qingdao Central Hospital |
Ma X.,Comprehensive Therapy Qingdao Central Hospital |
Sun C.,Comprehensive Therapy Qingdao Central Hospital |
And 2 more authors.
Cancer Research and Clinic | Year: 2015
Objective: To investigate the safety and clinical efficacy of recombinant human endostatin injection (endostar) continuous pumping combine with chemotherapy injection in the treatment of advanced malignancies. Methods: 156 patients with advanced cancer were divided into the chemotherapy group (78 cases) and the chemotherapy combined with endostar group (78 cases). The two groups were similar in the tumor types, the neoplasm staging, the KPS and the chemotherapy agents. After two cycles chemotherapy, the efficacy was evaluated according to RECIST criteria and the quality of life (QOL) was assessed by KPS scores. Results: The objective response rate (RR) of the chemotherapy combined with endostar group was 39.74% (31/78). The RR of the chemotherapy group was 17.95% (14/78). There was statistics significance in the RRs of the two groups (P < 0.05). The QOL of 42 cases (53.8%) were improved, 26 cases (33.3%) were in stable and 10 cases (12.8%) were decreased in the chemotherapy combined with endostar group. The QOL were improved in 30 cases (38.5%), stabled in 17 cases (21.8%) and decreased in 31 cases (39.7%) in the chemotherapy group. There were significant difference between the two groups (P < 0.05). The main adverse reactions were myelosuppression and digestive tract reaction in both groups (P > 0.05), and all patients can tolerate. Conclusion: The QOL of patients with advanced malignant tumors are improved by endostar combined with chemotherapy which is safe and effective. It is worthy further clinical observation.